BioCentury
ARTICLE | Company News

NICE spurns Amgen's Repatha

November 19, 2015 1:45 AM UTC

The U.K.'s NICE issued draft guidance recommending against the use of Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN), alone or in combination with lipid-lowering therapies, to treat primary hypercholesterolemia or mixed dyslipidemia.

The committee cited a lack of clinical evidence regarding the effect of Repatha on cardiovascular outcomes. Amgen spokesperson Kelley Davenport said Amgen expects top-line data in 2H16 from the FOURIER cardiovascular outcomes trial (CVOT) of Repatha. ...